Please use this identifier to cite or link to this item: https://hdl.handle.net/11499/5297
Title: Comparative study of 0.1% olopatadine hydrochloride and 0.5% ketorolac tromethamine in the treatment of seasonal allergic conjunctivitis
Authors: Yaylalı, Volkan
Demirlenk, İbrahim
Tatlıpınar, Sinan
Özbay, Davut
Esme, Arif
Yıldırım, Cem
Özden, Serap
Keywords: Ketorolac
Ocular allergy
Olopatadine
Seasonal allergic conjunctivitis
antazoline
antihistaminic agent
cromoglycate disodium
histamine H1 receptor antagonist
ketorolac trometamol
naphazoline
nonsteroid antiinflammatory agent
olopatadine
placebo
tears naturale
tears naturale ii
vasoconstrictor agent
adult
allergic conjunctivitis
article
clinical article
clinical trial
conjunctival hyperemia
controlled clinical trial
controlled study
drug activity
drug effect
drug efficacy
drug mechanism
female
human
lacrimation
male
mucus secretion
ocular pruritus
parallel design
priority journal
randomized controlled trial
scoring system
statistical significance
symptomatology
visual system parameters
Adolescent
Adult
Anti-Inflammatory Agents, Non-Steroidal
Conjunctiva
Conjunctivitis, Allergic
Dibenzoxepins
Female
Histamine H1 Antagonists
Humans
Hyperemia
Ketorolac Tromethamine
Male
Ophthalmic Solutions
Therapeutic Equivalency
Abstract: Purpose: To compare the therapeutic effects of two ophthalmic solutions (0.1% olopatadine hydrochloride and 0.5% ketorolac tromethamine) with different pharmacological mechanisms on the clinical signs and Symptoms of seasonal allergic conjunctivitis (SAC). Methods: Forty patients with the signs and symptoms of SAC (i.e. hyperaemia, itching, mucus discharge, tearing) were included in this placebo-controlled, randomized, parallel group, single centre study. In group 1 (20 patients) one eye of each patient was treated with olopatadine and the other with placebo. In group 2 (20 patients) one eye of each patient was treated with ketorolac solution and the other with placebo. The principal signs and symptoms of SAC (hyperaemia and itching) were evaluated at 30 mins and at 2, 7 and 15 days. Results: In group 1, both parameters improved significantly in eyes treated with olopatadine compared with those receiving placebo at all control examinations (all p<0.05). Similarly, eyes treated with ketorolac showed significant reductions in signs and symptoms compared with those receiving placebo (all p<0.05). When the clinical parameters of eyes treated with olopatadine were compared with those treated with ketorolac, the mean score of hyperaemia was found to be lower in the olopatadine group, but the difference was not statistically significant (all p>0.05). However, the itching score was significantly lower in the olopatadine group from the second day through to the end of the study (p<0.05). Conclusions: Both olopatadine and ketorolac ophthalmic solutions were found to be effective in alleviating the clinical signs and symptoms of SAC compared to placebo. However, olopatadine reduces ocular itching significantly more than ketorolac.
URI: https://hdl.handle.net/11499/5297
https://doi.org/10.1034/j.1600-0420.2003.00079.x
ISSN: 1395-3907
Appears in Collections:PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection
Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
Tıp Fakültesi Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection

Files in This Item:
File SizeFormat 
j.1600-0420.2003.00079.x.pdf103.6 kBAdobe PDFView/Open
Show full item record



CORE Recommender

SCOPUSTM   
Citations

54
checked on Oct 13, 2024

WEB OF SCIENCETM
Citations

43
checked on Dec 5, 2024

Page view(s)

86
checked on Aug 24, 2024

Download(s)

34
checked on Aug 24, 2024

Google ScholarTM

Check




Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.